GT Biopharma Inc（GTBP）資訊與事件GTBPGT Biopharma Inc

Selling Stockholders Plan to Sell Up to 13.5M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.5M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

GT Biopharma Trading Halted Due to Volatility

GT Biopharma trading halted, volatility trading pause

GT Biopharma Receives FDA IND Clearance for GTB-5550

GT Biopharma announced IND clearance from the FDA for GTB-5550 in multiple myeloma. "Today's IND to expand the potential indications for GTB-5550 highlights the diverse utility of our Trike(R) platform," said Michael Breen, executive chairman and CEO of GT Biopharma. "The company remains focused on its two ongoing Phase 1 trials with GTB-5550 and GTB-3650, both of which are actively enrolling, and we look forward to the potential initiation of a third Phase 1 trial, pending receipt of non-dilutive grant funding."